Eventide Asset Management - Q2 2020 holdings

$4.6 Billion is the total value of Eventide Asset Management's 134 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 63.2% .

 Value Shares↓ Weighting
ASND BuyASCENDIS PHARMA A Ssponsored adr$252,887,000
+32.2%
1,709,848
+0.7%
5.50%
-11.3%
EXAS BuyEXACT SCIENCES CORP$151,276,000
+87.4%
1,740,000
+25.0%
3.29%
+25.8%
IGV BuyISHARES TRput$137,700,000
+122.2%
600,000
+106.2%
2.99%
+49.2%
ROP BuyROPER TECHNOLOGIES INC$90,232,000
+35.2%
232,400
+8.6%
1.96%
-9.3%
PLRX NewPLIANT THERAPEUTICS INC$88,412,0002,838,125
+100.0%
1.92%
LOW BuyLOWES COS INC$81,058,000
+57.9%
599,900
+0.6%
1.76%
+6.0%
MTD BuyMETTLER TOLEDO INTERNATIONAL$73,305,000
+49.5%
91,000
+28.2%
1.59%
+0.4%
POOL BuyPOOL CORPORATION$67,750,000
+85.1%
249,200
+34.0%
1.47%
+24.3%
NEP BuyNEXTERA ENERGY PARTNERS LP$64,515,000
+20.7%
1,258,100
+1.2%
1.40%
-19.0%
IDXX BuyIDEXX LABS INC$58,108,000
+67.7%
176,000
+23.1%
1.26%
+12.6%
SMAR BuySMARTSHEET INC$56,674,000
+44.2%
1,113,000
+17.5%
1.23%
-3.2%
ODFL BuyOLD DOMINION FREIGHT LINE IN$52,607,000
+87.7%
310,200
+45.3%
1.14%
+26.1%
TREX BuyTREX CO INC$48,646,000
+103.0%
374,000
+25.1%
1.06%
+36.2%
RNG BuyRINGCENTRAL INCcl a$44,177,000
+72.3%
155,000
+28.1%
0.96%
+15.7%
NBIX BuyNEUROCRINE BIOSCIENCES INC$43,652,000
+42.9%
357,800
+1.4%
0.95%
-4.0%
ZNTL NewZENTALIS PHARMACEUTICALS INC$42,496,000914,705
+100.0%
0.92%
TT BuyTRANE TECHNOLOGIES PLC$41,999,000
+2468.7%
472,000
+2283.8%
0.91%
+1622.6%
DHI BuyD R HORTON INC$40,490,000
+80.7%
730,200
+10.8%
0.88%
+21.2%
VRSK BuyVERISK ANALYTICS INC$37,359,000
+69.6%
219,500
+38.9%
0.81%
+13.9%
KALA BuyKALA PHARMACEUTICALS INC$36,259,000
+39.7%
3,450,000
+16.8%
0.79%
-6.3%
MGA BuyMAGNA INTL INC$32,716,000
+42.7%
734,700
+2.3%
0.71%
-4.2%
RCKT BuyROCKET PHARMACEUTICALS INC$32,442,000
+64.4%
1,550,000
+9.5%
0.70%
+10.3%
FVRR NewFIVERR INTL LTD$29,402,000398,299
+100.0%
0.64%
TPTX NewTURNING POINT THERAPEUTICS I$24,738,000383,000
+100.0%
0.54%
CRNX BuyCRINETICS PHARMACEUTICALS IN$23,599,000
+69.5%
1,347,000
+42.2%
0.51%
+13.7%
CGNX NewCOGNEX CORP$21,439,000359,000
+100.0%
0.47%
NewTRILLIUM THERAPEUTICS INC$20,605,0002,547,000
+100.0%
0.45%
SWKS BuySKYWORKS SOLUTIONS INC$18,949,000
+56.8%
148,200
+9.6%
0.41%
+5.4%
MGTA BuyMAGENTA THERAPEUTICS INC$17,721,000
+57.7%
2,359,646
+31.8%
0.38%
+5.8%
BLU NewBELLUS HEALTH INC NEW$15,877,0001,543,000
+100.0%
0.34%
STRO BuySUTRO BIOPHARMA INC$15,411,000
+17.5%
1,985,975
+54.4%
0.34%
-21.2%
IMVT NewIMMUNOVANT INC$15,242,000625,950
+100.0%
0.33%
CIEN NewCIENA CORP$14,461,000267,000
+100.0%
0.31%
ARYA NewARYA SCIENCES ACQUISITION CO$12,592,000800,000
+100.0%
0.27%
ETNB Buy89BIO INC$11,460,000
+29.7%
575,000
+64.3%
0.25%
-12.9%
CCXI NewCHEMOCENTRYX INC$10,069,000175,000
+100.0%
0.22%
FENC BuyFENNEC PHARMACEUTICALS INC$9,352,000
+118.7%
1,120,000
+55.6%
0.20%
+46.0%
SNDX BuySYNDAX PHARMACEUTICALS INC$7,299,000
+193.5%
492,500
+117.3%
0.16%
+96.3%
ADCT NewADC THERAPEUTICS SA$7,021,000150,000
+100.0%
0.15%
CLDX NewCELLDEX THERAPEUTICS INC NEW$6,023,000463,335
+100.0%
0.13%
A BuyAGILENT TECHNOLOGIES INC$5,779,000
+71.3%
65,400
+38.9%
0.13%
+15.6%
ARE BuyALEXANDRIA REAL ESTATE EQ IN$5,387,000
+63.1%
33,200
+37.8%
0.12%
+9.3%
CHMA NewCHIASMA INC$5,186,000964,000
+100.0%
0.11%
PLD BuyPROLOGIS INC.$4,722,000
+49.5%
50,600
+28.8%
0.10%
+1.0%
NEE BuyNEXTERA ENERGY INC$4,587,000
+9.6%
19,100
+9.8%
0.10%
-26.5%
JKHY BuyHENRY JACK & ASSOC INC$4,472,000
+29.8%
24,300
+9.5%
0.10%
-13.4%
TER BuyTERADYNE INC$3,769,000
+128.8%
44,600
+46.7%
0.08%
+54.7%
WM BuyWASTE MGMT INC DEL$3,792,000
+35.2%
35,800
+18.2%
0.08%
-9.9%
ITT NewITT INC$3,654,00062,200
+100.0%
0.08%
FRC BuyFIRST REP BK SAN FRANCISCO C$3,413,000
+237.3%
32,200
+161.8%
0.07%
+124.2%
BuyEXACT SCIENCES CORPnote 1.000% 1/1$3,303,000
+315.5%
2,411,000
+230.3%
0.07%
+176.9%
AWK NewAMERICAN WTR WKS CO INC NEW$3,229,00025,100
+100.0%
0.07%
FHN NewFIRST HORIZON NATL CORP$3,229,000324,200
+100.0%
0.07%
STE NewSTERIS PLC$2,946,00019,200
+100.0%
0.06%
SHW BuySHERWIN WILLIAMS CO$2,831,000
+43.3%
4,900
+14.0%
0.06%
-3.1%
TCF NewTCF FINANCIAL CORPORATION NE$2,742,00093,200
+100.0%
0.06%
ZBH BuyZIMMER BIOMET HOLDINGS INC$2,530,000
+64.7%
21,200
+39.5%
0.06%
+10.0%
ARYAW NewARYA SCIENCES ACQUISITION CO*w exp 10/10/202$2,140,000400,000
+100.0%
0.05%
MSCI NewMSCI INC$1,202,0003,600
+100.0%
0.03%
NDAQ NewNASDAQ INC$920,0007,700
+100.0%
0.02%
ENTG NewENTEGRIS INC$844,00014,300
+100.0%
0.02%
BRBR NewBELLRING BRANDS INC$558,00028,000
+100.0%
0.01%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-08-14
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q2 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings